Targeting KRAS: from metabolic regulation to cancer treatment
Abstract The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-024-02216-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544927653134336 |
|---|---|
| author | Yanyan Shi Huiling Zheng Tianzhen Wang Shengpu Zhou Shiqing Zhao Mo Li Baoshan Cao |
| author_facet | Yanyan Shi Huiling Zheng Tianzhen Wang Shengpu Zhou Shiqing Zhao Mo Li Baoshan Cao |
| author_sort | Yanyan Shi |
| collection | DOAJ |
| description | Abstract The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance. Here, we review the metabolic reprogramming of glucose, glutamine, and lipids regulated by oncogenic KRAS, with an emphasis on recent insights into the relationship between changes in metabolic mechanisms driven by KRAS mutant and related advances in targeted therapy. We also focus on advances in KRAS inhibitor discovery and related treatment strategies in colorectal, pancreatic, and non-small cell lung cancer, including current clinical trials. Therefore, this review provides an overview of the current understanding of metabolic mechanisms associated with KRAS mutation and related therapeutic strategies, aiming to facilitate the understanding of current challenges in KRAS-driven cancer and to support the investigation of therapeutic strategies. |
| format | Article |
| id | doaj-art-6d7a8d38098743909ff8bd8e5bb3b117 |
| institution | Kabale University |
| issn | 1476-4598 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj-art-6d7a8d38098743909ff8bd8e5bb3b1172025-01-12T12:10:29ZengBMCMolecular Cancer1476-45982025-01-0124112110.1186/s12943-024-02216-3Targeting KRAS: from metabolic regulation to cancer treatmentYanyan Shi0Huiling Zheng1Tianzhen Wang2Shengpu Zhou3Shiqing Zhao4Mo Li5Baoshan Cao6Research Center of Clinical Epidemiology, Peking University Third HospitalDepartment of Gastroenterology, Peking University Third HospitalState Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third HospitalResearch Center of Clinical Epidemiology, Peking University Third HospitalResearch Center of Clinical Epidemiology, Peking University Third HospitalState Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third HospitalDepartment of Medical Oncology and Radiation Sickness, Peking University Third HospitalAbstract The Kirsten rat sarcoma viral oncogene homolog (KRAS) protein plays a key pathogenic role in oncogenesis, cancer progression, and metastasis. Numerous studies have explored the role of metabolic alterations in KRAS-driven cancers, providing a scientific rationale for targeting metabolism in cancer treatment. The development of KRAS-specific inhibitors has also garnered considerable attention, partly due to the challenge of acquired treatment resistance. Here, we review the metabolic reprogramming of glucose, glutamine, and lipids regulated by oncogenic KRAS, with an emphasis on recent insights into the relationship between changes in metabolic mechanisms driven by KRAS mutant and related advances in targeted therapy. We also focus on advances in KRAS inhibitor discovery and related treatment strategies in colorectal, pancreatic, and non-small cell lung cancer, including current clinical trials. Therefore, this review provides an overview of the current understanding of metabolic mechanisms associated with KRAS mutation and related therapeutic strategies, aiming to facilitate the understanding of current challenges in KRAS-driven cancer and to support the investigation of therapeutic strategies.https://doi.org/10.1186/s12943-024-02216-3KRAS-driven cancersCancer metabolismKRAS inhibitorsMetabolic reprogramming |
| spellingShingle | Yanyan Shi Huiling Zheng Tianzhen Wang Shengpu Zhou Shiqing Zhao Mo Li Baoshan Cao Targeting KRAS: from metabolic regulation to cancer treatment Molecular Cancer KRAS-driven cancers Cancer metabolism KRAS inhibitors Metabolic reprogramming |
| title | Targeting KRAS: from metabolic regulation to cancer treatment |
| title_full | Targeting KRAS: from metabolic regulation to cancer treatment |
| title_fullStr | Targeting KRAS: from metabolic regulation to cancer treatment |
| title_full_unstemmed | Targeting KRAS: from metabolic regulation to cancer treatment |
| title_short | Targeting KRAS: from metabolic regulation to cancer treatment |
| title_sort | targeting kras from metabolic regulation to cancer treatment |
| topic | KRAS-driven cancers Cancer metabolism KRAS inhibitors Metabolic reprogramming |
| url | https://doi.org/10.1186/s12943-024-02216-3 |
| work_keys_str_mv | AT yanyanshi targetingkrasfrommetabolicregulationtocancertreatment AT huilingzheng targetingkrasfrommetabolicregulationtocancertreatment AT tianzhenwang targetingkrasfrommetabolicregulationtocancertreatment AT shengpuzhou targetingkrasfrommetabolicregulationtocancertreatment AT shiqingzhao targetingkrasfrommetabolicregulationtocancertreatment AT moli targetingkrasfrommetabolicregulationtocancertreatment AT baoshancao targetingkrasfrommetabolicregulationtocancertreatment |